VEGFA and colorectal carcinoma: The limited efficacy of the combination of standard chemotherapy options (FOLFIRI or FOLFOX) with specific monoclonal antibodies (mAbs), such as those against vascular endothelial growth factor (VEGF) or endothelial growth factor receptor, has prompted researchers to seek novel strategies for the treatment of CRC [4].